Bulletin
Investor Alert

Oct. 22, 2021, 7:40 a.m. EDT

People who got J&J’s COVID-19 shot can get a booster. Which one should they get?

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Johnson & Johnson (JNJ)
  • X
    BioNTech SE ADR (BNTX)
  • X
    Pfizer Inc. (PFE)

or Cancel Already have a watchlist? Log In

Jaimy Lee

The 15 million people in the U.S. who got Johnson & Johnson’s COVID-19 vaccine now have the option to get a second shot of their choosing. 

The Food and Drug Administration on Wednesday authorized a second dose of J&J’s /zigman2/quotes/201724570/composite JNJ -0.63% adenovirus-based vaccine for all adults initially vaccinated with this shot.

The regulator is also allowing people to “mix and match” their boosters, meaning they can pick a mRNA vaccine or stick with the J&J shot for their booster dose. 

The FDA had already authorized BioNTech SE /zigman2/quotes/214419716/composite BNTX -0.30% and Pfizer Inc.’s /zigman2/quotes/202877789/composite PFE -3.00% booster for the elderly, people with underlying health conditions that put them at high risk of severe disease, and adults who live and work in high-risk settings. It issued a similar authorization on Wednesday for Moderna Inc.’s /zigman2/quotes/205619834/composite MRNA -2.94% booster. 

The months-long debate around boosters has almost entirely focused on the mRNA shots and has rarely mentioned J&J’s vaccine. It’s an omission that’s been criticized by some public-health experts — Dr. Leana Wen tweeted in August that J&J recipients, herself included, were being “left out.”

It’s also frustrating for the people who got the J&J shot and have been stuck waiting to see what happens. 

“There’s eagerness among many J&J recipients to be included on the booster train,” said Dr. David Wohl, an infectious-disease doctor and professor at the Institute of Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill. “What I tell them is: that train’s coming, and we just have to figure out what it exactly is going to look like.”

Research indicates that COVID-19 boosters are safe. About 10 million people in the U.S. have already received a booster shot, primarily of Pfizer’s vaccine, according to the Centers for Disease Control and Prevention .

The latest news is that an influential study conducted by the National Institutes of Health that came out last week found that mixing vaccines can dramatically boost antibody levels in J&J people who got a Moderna or Pfizer booster. 

But even physicians have different opinions about the best way to boost immunity in those who were initially vaccinated with the Johnson & Johnson vaccine. 

“I’m not sure that the totality of the science…is going to be super clear and conclusive in terms of saying it’s better to get this to boost than another vaccine,” said Dr. Angela Branche, an infectious-disease physician at the University of Rochester Medical Center who worked on the NIH study. 

Part of this tension has to do with the fact that it’s difficult to make apples-to-apples comparisons for different types of vaccines. Though the mRNA and adenovirus-based shots similarly protect against severe disease, hospitalization and death, the J&J shot has always been less effective against symptomatic infection than Pfizer or Moderna’s vaccines. 

“As with anything, you have to see what happens to the immune system over time,” said Dr. Michael Nelson, an immunologist at UVA Health and a member of the FDA’s advisory committee on vaccines. “Although this particular vaccine seems to be lasting a little bit longer than the messenger RNA vaccine, it’s good to be ahead of the curve and not wait for a second signal for people to start getting sick who were previously vaccinated.”

What the data tells us about antibody response and J&J’s ‘durability’ of protection 

The study detailing antibody responses using all three COVID-19 vaccines as boosters found that a Moderna booster for J&J recipients produced the highest antibody levels 15 days after a second shot, followed by Pfizer and then J&J. 

This is important for many people, especially those who are worried about a breakthrough infection that could lead to severe disease. 

But there are also some limitations to the research, which is considered preliminary. There were only about 450 participants, immunity was assessed using antibody titers—T-cell and B-cell responses are also considered important metrics—and it wasn’t designed to compare the different vaccine combinations.

/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 157.09
-0.99 -0.63%
Volume: 11.33M
Dec. 2, 2021 4:00p
P/E Ratio
23.48
Dividend Yield
2.70%
Market Cap
$416.16 billion
Rev. per Employee
$613,918
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 333.49
-0.99 -0.30%
Volume: 4.12M
Dec. 2, 2021 4:00p
P/E Ratio
9.63
Dividend Yield
N/A
Market Cap
$81.12 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 53.04
-1.64 -3.00%
Volume: 46.36M
Dec. 2, 2021 4:02p
P/E Ratio
15.74
Dividend Yield
2.94%
Market Cap
$306.91 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 301.49
-9.12 -2.94%
Volume: 15.41M
Dec. 2, 2021 4:00p
P/E Ratio
18.52
Dividend Yield
N/A
Market Cap
$125.94 billion
Rev. per Employee
$617,996
loading...
1 2
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.